A retrospective longitudinal study to determine whether specific time-of-day patterns of immune checkpoint inhibitor infusions changes melanoma treatment efficacy
Latest Information Update: 22 Nov 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms MEMOIR
- 22 Nov 2021 New trial record
- 12 Nov 2021 Results (n=299) of analysis assessing safety and efficacy from participant-level data from MEMOIR database with stage IV melanoma published in the Lancet Oncology